Intravenous nitroglycerine in refractory unstable angina pectoris

Area of Science:

• Cardiology
• Pharmacology

Background:

• Severe coronary artery disease and unstable angina often present challenges in management.
• Standard therapies including nitrates, beta-blockers, and calcium antagonists may be insufficient for refractory cases.

Purpose of the Study:

• To evaluate the efficacy and safety of intravenous nitroglycerin in patients with severe coronary artery disease and unstable angina.
• To assess pain relief and hemodynamic response to intravenous nitroglycerin in a refractory patient population.

Main Methods:

• An open-label trial involving sixteen patients with severe coronary artery disease and unstable angina.
• Administration of intravenous nitroglycerin, with infusion rates adjusted based on individual patient response.
• Monitoring of pain, hemodynamic parameters (systolic blood pressure, heart rate), and adverse effects.

Main Results:

• All patients experienced significant pain relief, with complete relief in six individuals.
• Occasional, less severe episodes of chest pain with fewer ST segment changes were noted in ten patients during infusion.
• A mean decrease in systolic blood pressure of 100 mmHg was observed, with no significant heart rate changes; mild headaches were the primary adverse effect.

Conclusions:

• Intravenous nitroglycerin provides effective pain relief for patients with severe coronary artery disease and unstable angina refractory to conventional therapies.
• The treatment is associated with acceptable hemodynamic changes and a favorable safety profile, with mild headaches as the main side effect.
• Intravenous nitroglycerin serves as a valuable therapeutic option, potentially bridging patients to oral/cutaneous nitrate therapy or coronary artery surgery.